GAITHERSBURG, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (GMI), a privately held firm that is developing a new class of glycobiology-based therapies for a broad range of indications, today presented the results of in vivo animal models that demonstrate the activity of its lead drug candidate at an international glycobiology conference.
